Stock Events

Stock Events

Grace Therapeutics 

$2.12
173
-$0.04-1.85% Friday 20:00
+$0.02+1.18%Friday 23:37After hours

Statistics

Day High
2.13
Day Low
2.12
52W High
5.18
52W Low
1.79
Volume
1,714
Avg. Volume
-
Mkt Cap
44.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q2 2026
Next
-0.91
-0.57
-0.23
0.11
Expected EPS
-0.15
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
0Revenue
-12.85MNet Income

Analyst Ratings

8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRCE. It's not an investment recommendation.
NVIDIA
13
NVDA
Microsoft
12
MSFT
Amazon
12
AMZN
Alphabet
12
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amarin
AMRN
Mkt Cap297.62M
Amarin Corporation plc focuses on the development and commercialization of therapeutics for cardiovascular health, directly competing with Acasti Pharma's focus on omega-3 phospholipids for similar conditions.
Astrazeneca
AZN
Mkt Cap257.42B
AstraZeneca PLC, a large pharmaceutical company, has a diverse portfolio that includes treatments for cardiovascular diseases, competing with Acasti Pharma's cardiovascular focus.
Pfizer
PFE
Mkt Cap159.99B
Pfizer Inc. has a broad range of products including treatments for cardiovascular diseases, making it a competitor to Acasti Pharma in the cardiovascular therapeutic area.
Merck
MRK
Mkt Cap376.37B
Merck & Co., Inc. offers a wide range of healthcare solutions, including cardiovascular disease treatments, competing with Acasti Pharma's product offerings.
Novartis
NVS
Mkt Cap301.95B
Novartis AG, with its extensive research and development in cardiovascular diseases, competes with Acasti Pharma in the market for cardiovascular health solutions.
GSK
GSK
Mkt Cap104.97B
GlaxoSmithKline plc has a diversified portfolio that includes cardiovascular drugs, making it a competitor to Acasti Pharma in the cardiovascular space.
Abbvie
ABBV
Mkt Cap468.22B
AbbVie Inc. engages in the discovery, development, manufacture, and sale of a broad line of pharmaceuticals, including those for cardiovascular diseases, competing with Acasti Pharma.
AMGEN
AMGN
Mkt Cap237.52B
Amgen Inc. focuses on human therapeutics, including cardiovascular disease treatments, which positions it as a competitor to Acasti Pharma.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol-Myers Squibb Company offers a wide range of prescription pharmaceuticals in several therapeutic areas, including cardiovascular diseases, competing with Acasti Pharma's focus.

Holdings

Regions

Sectors

About

Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Show more...
CEO
Prashant Kohli
Employees
5
Country
United States
ISIN
US00439U1043
WKN
000A423YD

Listings

F
DE
A1P0.F
MI
IT
AIPO.MI
XETRA
DE
A1P0.XETRA
STU
DE
L8S.STU

0 Comments

Share your thoughts

FAQ

What is Grace Therapeutics stock price today?▼
The current price of GRCE is $2.12 USD — it has decreased by -1.85% in the past 24 hours. Watch Grace Therapeutics stock price performance more closely on the chart.
What is Grace Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Grace Therapeutics stocks are traded under the ticker GRCE.
Is Grace Therapeutics stock price growing?▼
GRCE stock has fallen by -3.64% compared to the previous week, the month change is a +2.42% rise, over the last year Grace Therapeutics has showed a -30.03% decrease.
What is Grace Therapeutics market cap?▼
Today Grace Therapeutics has the market capitalization of 44.6M
When is the next Grace Therapeutics earnings date?▼
Grace Therapeutics is going to release the next earnings report on November 16, 2026.
What were Grace Therapeutics earnings last quarter?▼
GRCE earnings for the last quarter are -0.91 USD per share, whereas the estimation was -0.13 USD resulting in a -603.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Grace Therapeutics revenue for the last year?▼
Grace Therapeutics revenue for the last year amounts to 0 USD.
What is Grace Therapeutics net income for the last year?▼
GRCE net income for the last year is -12.85M USD.
How many employees does Grace Therapeutics have?▼
As of August 30, 2026, the company has 5 employees.
In which sector is Grace Therapeutics located?▼
Grace Therapeutics operates in the Health & Wellness sector.
When did Grace Therapeutics complete a stock split?▼
The last stock split for Grace Therapeutics was on July 10, 2023 with a ratio of 1:6.
Where is Grace Therapeutics headquartered?▼
Grace Therapeutics is headquartered in PRINCETON, United States.